|
|
|
| miR-145 promotes the pathological process of acute Kawasaki disease by downregulating the target gene ACVR1B |
| LYU Dianyi WU Fuxia CHEN Fengyi |
| Department of Pediatrics, Yichang First People′s Hospital, Hubei Province, Yichang 443000, China |
|
|
|
Abstract Objective To investigate the effect of down-regulation of ACVR1B gene by miR-145 in promoting the pathological process of acute Kawasaki disease (KD). Methods A total of 108 children who were treated in Yichang First People′s Hospital from November 2015 to June 2018 were included in the retrospective analysis, according to the disease conditions, children were divided into acute KD group (n = 28), with a confirmed diagnosis of acute KD; KD recovery group (n = 24), who was admitted to the hospital during the same period and in the recovery stage after treatment; pyrexia control group (n = 30), who had pyrexia due to upper respiratory tract infection; and normal control group (n = 26), who underwent physical examination during the same period. Serum was taken from the patients to check the expression level of miR-145. Target gene database was searched, and chemical-activated luciferase gene expression, qRT-PCR, and Western blot were performed. Results The white blood cell count, C-reactive protein, and erythrocyte sedimentation rate of acute KD group were significantly higher than the normal control group (P < 0.05), the acute KD group had significantly higher expression of miR-145 in serum than the KD recovery group, the pyrexia control group, and the normal control group (P < 0.05). The expression level of ACVR1B mRNA in serum of the fever control group was significantly lower than that of the normal control group (P < 0.05). The expression level of ACVR1B mRNA in serum of the acute KD group was significantly lower than that of the normal control group, the fever control group and the KD rehabilitation group (P < 0.05). Conclusion miR-145 can bind the 3′-UTR of ACVR1B and inhibit the expression of ACVR1B, and the regulatory relationship between miR-145 and ACVR1B can promote the pathological development of acute KD.
|
|
|
|
|
|
[1] 段炤，林智平，刘青，等.CD4CD调节性T淋巴细胞与辅助性T淋巴细胞17在川崎病发病机制中的作用[J].中华实用儿科临床杂志，2017，32（9）：652-655.
[2] 苏丹艳，庞玉生.川崎病合并巨大冠状动脉瘤的诊治进展[J].广西医科大学学报，2014，31（4）：715-717.
[3] 刘潇婷，朝鲁门.川崎病的动物模型及其发病机制研究进展[J].内蒙古医科大学学报，2016，38（6）：585-590.
[4] 林瑞峰，李红，陈小夏，等.丙种球蛋白联合阿司匹林治疗川崎病34例临床疗效观察[J].数理医药学杂志，2015，（6）：872-873.
[5] 史长松，杨中文，程艳波，等.静脉注射丙种球蛋白无反应不完全川崎病并巨大冠状动脉瘤一例[J].中国小儿急救医学，2016，23（9）：647-648.
[6] 章凯，王建洪，罗小邹.鼻咽癌易感TERT基因的多种靶microRNA在鼻咽癌患者血清中表达量变化及其临床诊断价值[J].中国耳鼻咽喉头颈外科，2018，25（1）：13-16.
[7] 董丽华，舒亚南，薛震颖，等.PDGF-BB下调血管平滑肌标志物SM22α表达的机制[J].中国细胞生物学学报，2012， 34（8）789-794.
[8] 牛倩，赵小燕，王婧.川崎病患儿46例优质化护理研究[J].陕西医学杂志，2015，44（4）：512-513.
[9] 沈杰，章毅英，解春红，龚方戚.川崎病患儿血浆吲哚胺2，3双加氧酶含量的研究[J].临床医药实践，2017，26（4）：253-255.
[10] 金雷皓.microRNA-663对羊驼黑色素细胞黑色素合成的影响[D].晋中：山西农业大学，2014.
[11] 褚茂平，周爱华，胡晨，等.miR-130a和miR-125b在川崎病外周血细胞中的表达及意义[J].浙江医学，2015， 37（5）：357-362.
[12] 崔萍萍，李成荣，李秋，等.微小RNA-155/微小RNA-21对急性期川崎病Toll样受体4表达的影响[J].中华风湿病学杂志，2015，19（12）：813-818.
[13] 梅洁花，王勤，温鹏强，等.急性期川崎病IL-17基因组蛋白甲基化修饰改变及意义[J].中华微生物学和免疫学杂志，2016，36（9）：692-698.
[14] 汪燕燕，郑思道，于雯.microRNA在糖尿病心血管损伤中的作用和意义[J].宁夏医学杂志，2013，35（2）：185-188.
[15] 严晓华，白涛敏，马娟，等.儿童川崎病患者血浆和肽素，IL-17A，TNF-α检测与冠脉病变的相关性研究[J].现代检验医学杂志，2017，32（6）：50-52.
[16] 雷桅，税晓容，陈灿.microRNA在冠心病发生机制中的作用及其临床应用[J].广东医学，2014，35（17）：2773-2776.
[17] 陈雪贞，覃丽君，吴若豪，等.微小RNA在川崎病患儿中的研究进展[J].中国实用儿科杂志，2018，33（2）：152-155.
[18] 张松跃，任跃，何跃娥，等.尾加压素Ⅱ受体拮抗剂对高肺血流性肺动脉高压大鼠肺组织TGF-β1表达的影响[J].温州医科大学学报，2018，48（6）：55-59.
[19] 刘镕，赵琴平，董惠芬，等.TGF-β信号传导通路及其生物学功能[J].中国病原生物学杂志，2014，9（1）：77-83.
[20] 龙隆，李菲菲，刘洪英，等.激活素受体样激酶4，5和7抑制剂体外高通量筛选模型的构建[J].中国药理学与毒理学杂志，2017，31（6）：581-589. |
|
|
|
